Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cellectar Biosc (CLRB)

1.22   0.02 (1.67%) 10-23 23:38
Open: 1.22 Pre. Close: 1.2
High: 1.22 Low: 1.19
Volume: 144,425 Market Cap: 34M
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 15 full-time employees. The firm is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The firm's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.221 - 1.228 1.228 - 1.235
Low: 1.173 - 1.181 1.181 - 1.19
Close: 1.207 - 1.219 1.219 - 1.232

Technical analysis

as of: 2020-10-23 4:42:02 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.52     One year: 1.62
Support: Support1: 1.16    Support2: 0.97
Resistance: Resistance1: 1.30    Resistance2: 1.39
Pivot: 1.26
Moving Average: MA(5): 1.22     MA(20): 1.25
MA(100): 1.29     MA(250): 1.64
MACD: MACD(12,26):     Signal(9):
Stochastic oscillator: %K(14,3): 14.29     %D(3): 17.82
RSI: RSI(14): 47.51
52-week: High: 3.33  Low: 1.01  Change(%): -22.3
Average Vol(K): 3-Month: 47455  10-Days: 14428

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CLRB has closed above bottom band by 28.1%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to CLRB's normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Fri, 16 Oct 2020
38 Stocks Moving in Friday's Pre-Market Session - Benzinga

Wed, 07 Oct 2020
Are You Looking For Active Stock? Cellectar Biosciences (CLRB) - Digital Market News

Wed, 07 Oct 2020
Wall Street Analysts Are Bullish on Top Healthcare Picks - Smarter Analyst

Wed, 30 Sep 2020
How Does Cellectar Biosciences Inc (CLRB) Stock Rank on Wall Street? - InvestorsObserver

Mon, 14 Sep 2020
Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look - Seeking Alpha

Thu, 10 Sep 2020
Cellectar Biosciences to Present at Two Upcoming Investor Conferences - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 27
Shares Float (M) 24
% Held by Insiders 2.58
% Held by Institutions 29.70
Shares Short (K) 1,030
Shares Short P. Month (K) 1,050

Stock Financials

EPS -1.414
EPS Est This Year -0.920
EPS Est Next Year -0.870
Book Value (p.s.) 0.740
Profit Margin
Operating Margin
Return on Assets (ttm) -43.2
Return on Equity (ttm) -82.6
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.552
Qtrly Earnings Growth
Operating Cash Flow (M) -13
Levered Free Cash Flow (M) -7

Stock Valuations

PE Ratio -0.86
PEG Ratio
Price to Book value 1.65
Price to Sales
Price to Cash Flow -2.54

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.